Ascend Advanced Therapies Welcomes New Board Members
Ascend Advanced Therapies has made significant strides in its leadership with the recent appointments of John Chiminski and Karen Flynn to its Board of Directors. Chiminski will assume the role of Chair, while Flynn comes on board as an independent director. These appointments are seen as a crucial move for Ascend as the company aims to strengthen its position in the advanced therapy development sector.
Experience and Vision of New Leaders
John Chiminski brings over 30 years of extensive experience in the healthcare and pharmaceutical sectors. He previously held prominent roles, including his tenure as CEO of Catalent, where he played a key role in transforming it into a leading contract development and manufacturing organization (CDMO). His visionary approach and understanding of the industry are expected to guide Ascend as it navigates its growth trajectory.
In his words, "Ascend is at a pivotal moment in its growth, and I am excited to support the team as we build a world-class gene therapy CDMO. With the right strategy, investment, and operational excellence, Ascend is well-positioned to be a leading partner in advanced therapies."
Karen Flynn's Strategic Contributions
Karen Flynn, with her robust background in commercial operations, will add a wealth of knowledge to Ascend's board. Previously, she served as the Interim President of BioModalities at Catalent, where she honed her skills in managing complex operations and strategic initiatives. Flynn has held several critical positions, equipping her with a comprehensive understanding of the intricacies involved in the biopharmaceutical industry.
Flynn expressed her excitement, stating, "With the addition of ABL, Inc. and investment by EW Healthcare Partners, the Ascend network can support gene therapy, oncolytic, vaccine, immunotherapy, and government customers at all stages of development through to fill/finish. This is a world-class offering built to support customers long term."
The Road Ahead for Ascend Advanced Therapies
The management team at Ascend is enthusiastic about the future, especially with the addition of Chiminski and Flynn. Mike Stella, the CEO of Ascend, remarked on the strategic expertise both leaders bring to the company: "We are excited to welcome John and Karen to the board, and their counsel will be instrumental as we scale up our capabilities in manufacturing advanced therapies."
Ascend Advanced Therapies specializes in developing high-quality gene therapies and has recently partnered with EW Healthcare Partners. This partnership has not only expanded Ascend's capabilities but also its reach across multiple facilities in the U.S. and Europe. The company is set to support clients through every stage of the development process, from clinical trials to commercial success.
About Ascend Advanced Therapies
Ascend Advanced Therapies is dedicated to providing comprehensive solutions for advanced therapy development and manufacturing. With a focus on cost-effective, high-quality outcomes, Ascend collaborates with clients to ensure their needs are met efficiently. With its diverse portfolio, Ascend is prepared to handle gene therapies, oncolytics, vaccines, and immunotherapies, making it a vital player in the contemporary pharmaceutical landscape.
Frequently Asked Questions
What is the significance of appointing John Chiminski as Chair?
John Chiminski's leadership will drive strategic growth and expand Ascend's influence in advanced therapies.
What background does Karen Flynn bring to the board?
Karen Flynn has extensive experience in commercial and operational roles within the pharmaceutical industry, which will benefit Ascend.
How will these appointments impact Ascend's operations?
The new leadership is expected to enhance operational excellence and strategic initiatives, positioning Ascend for future growth.
What is Ascend's focus as a company?
Ascend specializes in gene therapy development and manufacturing, aiming for high-quality, cost-effective solutions.
How does the partnership with EW Healthcare Partners benefit Ascend?
This partnership expands Ascend's capabilities and resources, enabling support for various therapy types across multiple development stages.
